Scientific program

Download the program as a PDF-file here

Wednesday 16/11
08.00-09.30
Sponsored symposia

8.00-8.30 Symposia 1: AstraZeneca
Covid-19 and transplant patients
(John Søfteland, Sahlgrenska University Hospital)

8.30-9.00 Symposia 2: GSK
Practicalities of setting up and running a Covid medicines delivery unit and administering sotrovimab
(Cecilia Priestley & Sarah Williams, Dorset County Hospital NHS Foundation Trust)

9.00-9.30 Symposia 3: Pfizer
Neandertal gene variants and COVID-19
(Hugo Zeberg, Karolinska Institutet)

09.30-09.45
Pause
09.45-10.00
Opening

Lars-Magnus Andersson, Sahlgrenska University Hospital/Östra
Anders Johansson, University Hospital of Umeå, Umeå University
Martin Sundqvist, Örebro University Hospital, Örebro University

10.00-11.30
Virology and diagnostics

Moderator: Jan Albert, Karolinska Institutet & Magnus Lindh, Sahlgrenska University Hospital

The evolution of SARS-CoV-2. Where are we heading?
(Emma Hodcroft, University of Bern)

Viral kinetics during SARS-CoV-2 infection
(Christopher Chiu, Imperial College London)

Less is more? Ct-values for quantitation beyond Covid-19
(Emmi Andersson, Public Health Agency of Sweden)

Discussion

11.30-12.30
Lunch
12.30-14.00
Immunology and vaccines

Moderator: Marcus Buggert, Karolinska Institutet & Anna Smed Sörensen, Karolinska Institutet

Antibody responses to SARS-CoV-2 infection and vaccination
(Florian Krammer, Icahn School of Medicine at Mount Sinai)

Longitudinal responses to mRNA vaccination at Elderly Care Homes in Sweden
(Mattias Forsell, Umeå University)

Vaccination in older adults
(Dorota Religa, Karolinska Institutet)

Discussion

14.00-14.30
Pause
14.30-16.00
Epidemiology

Moderator: Anders Johansson, Umeå University Hospital, Umeå University

Who is most at risk of dying from COVID-19? Using UK patient records to investigate in a pandemic
(Helen McDonald, London School of Hygiene and Tropical Medicine)

Excess mortality during pandemics – not so easy to measure as it may seem
(Jonas Björk, Lund University)

Prospects for real-time surveillance at the human-animal interface
(Fernanda Dórea, National Veterinary Institute)

Discussion
16.00-17.00
Oral poster presentations

Moderator: Martin Sundqvist, Örebro University Hospital, Örebro University

O1: Impaired diffusion capacity after COVID-19 is not associated with self-perceived breathlessness or non-physiological responses to exertion
(Johan Normark, Umeå University)

O2: SARS-CoV-2 vaccination boosts neutralising antibodies in the upper respiratory tract in previously infected individuals
(Julia Svensson, Karolinska Institutet)

O3: Monocyte infiltration, dendritic cell depletion in blood and airways and functional deficits in blood associate with COVID-19 severity but normalize
(Björn Österberg, Karolinska Institutet)

O4: Immunogenicity and safety of coadministration of COVID-19 and influenza vaccination among healthcare workers
(Isabell Wagenhäuser, University Hospital Wuerzburg)

O5: Occupational variation in the risk of Covid-19 infection and hospitalization among foreign-born healthcare workers in Sweden: a registry-based study
(Chioma Nwaru, University of Gothenburg)

O6: One-year mortality and hospital-free days in COVID-19 versus non-COVID-19 critical illness
(Pontus Hedberg, Karolinska Institutet et al.) 

17.00-18.00
Poster mingle
Thursday 17/11
08.00-09.30
Sponsored symposia

8.00-8.30 Symposia 4: Pfizer
Swedish national registry based research on COVID-19 during the pandemic
(Peter Nordström, Umeå University)

8.30-9.00 Symposia 5: AstraZeneca
The Role of Monoclonal Antibodies in Prophylaxis and Treatment of Covid-19
– The Perspective of an Oncologist/Hematologist
(Hans Hagberg, Uppsala University Hospital)

9.00-9.30 Symposia 6: GSK
Treatment of Covid-19 in 2022 – focus on unmet medical need
(Marta Boffito, Chelsea and Westminster Hospital, Imperial College London)

09.30-10.00
Pause
10.00-11.30
Clinical syndromes and pathogenesis

Moderator: Magnus Gisslén, Sahlgrenska University Hospital

Current understanding of pathogenesis in relation to clinical presentation of COVID-19
(Jesus Bermejo-Martin, Instituto de Investigación Biomédica de Salamanca)

Neuro-COVID – clinical picture and pathogenesis
(Arvid Edén,
University of Gothenburg)

COVID-19 in older adults – clinical aspects
(Maria Eriksdotter, Karolinska Institutet)

Discussion

11.30-12.30
Lunch
12.30-14.00
Management and treatment

Moderator: Anders Sönnerborg, Karolinska University Hospital/Karolinska Institutet

Management and treatment keynote
(Carlos Del Rio, Emory University School of Medicine)

Evidence based treatment of Covid-19
(Sara Cajander, Örebro University)

Covid treatment in patients with immunosuppression
(Piotr Nowak, Karolinska University Hospital/Karolinska Institutet)

Discussion

14.00-14.30
Pause
14.30-16.00
Infection Prevention

Moderator: Martina Wahllöf, Sahlgrenska University Hospital

Aerosols and Disease Transmission: From Source to Survival
(Jonathan Reid, University of Bristol)

When and where do we find SARS-CoV-2 in hospital air?
(Jakob Löndahl, Lund University)

Clinical aspects – ”Lessons learned and future perspectives”
(Carl-Johan Fraenkel, Lund University)

Discussion

16.00-16.30
Unresolved research questions

Moderator: Lars-Magnus Andersson, Sahlgrenska University Hospital/Östra

Panel:
Magnus Lindh, Sahlgrenska University Hospital
Marcus Buggert, Karolinska Institutet
Anna Smed Sörensen, Karolinska Institutet
Anders Johansson, Umeå University Hospital, Umeå University
Martin Sundqvist, Örebro University Hospital, Örebro University
Magnus Gisslén, Sahlgrenska University Hospital

16.30-17.00
Close and poster award

Niklas Lundblad, Mediahuset